Chemiluminescence Immunoassay Market

The chemiluminescence immunoassay market is projected to reach USD 16.39 billion by 2031, from USD 11.58 billion in 2026, at a CAGR of 7.2% from 2026 to 2031.

The chemiluminescence imamunoassay market experiences expansion because there is an increasing worldwide demand for precise diagnostic tests, which are needed to diagnose chronic diseases and infectious diseases that include cancer, cardiovascular diseases, thyroid disorders, and viral diseases. The high sensitivity of CLIA technology, combined with its capability to quantify a broad dynamic range of analyte concentrations and detect low-abundance biomarkers, has accelerated its adoption across clinical settings.

To know about the assumptions considered for the study download the pdf brochure

The growing emphasis on early disease detection and preventive healthcare further supports increased utilization of CLIA-based testing. Laboratory operations become more efficient through technological innovations, including automated systems for high-throughput testing, new methods to keep reagents stable, and systems that can conduct multiple tests at once.

Market growth is supported by three factors: the development of healthcare systems, the expansion of diagnostic laboratory networks, and the rise in healthcare expenditures across developing countries. The demand for personalized medicine and biomarker-based testing in pharmaceutical research and the growing blood screening needs for transfusion safety create a stronger demand for healthcare services. CLIA has established itself as a key diagnostic technology used by hospitals and reference laboratories for standard testing of hormones, infectious diseases, and oncology.

Some of the prominent players operating in the market include The key players in the market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), DiaSorin S.p.A. (Italy), QuidelOrtho Corporation (US), Sysmex Corporation (Japan), Shenzhen New Industry Biomedical Engineering Co., Ltd. (SNIBE Diagnostics) (China), Tosoh Corporation (Japan), Werfen (Spain), Bio-Rad Laboratories, Inc. (US), Shenzhen Mindray Biomedical Electronics Co., Ltd. (China), Fujirebio (Japan), and Shanghai Kehua Bio-Engineering Co., Ltd. (China)., among others.

F. Hoffmann-La Roche Ltd. (Switzerland)

Roche Diagnostics is one of the leading companies because it provides a comprehensive system of immunodiagnostic tests, operates worldwide, and develops new laboratory testing technologies. The company’s cobas e series analyzers and Elecsys immunoassay tests are used by medical facilities for testing needs, including oncology, infectious diseases, cardiac markers, endocrine disorders, and fertility diagnostics. Laboratories use Roche’s CLIA systems because they provide exceptional sensitivity, consistent assay performance, and automated processes that help labs work faster and complete tests sooner. The company maintains its top market position through its broad range of FDA and CE-approved tests and its active efforts to discover new biomarkers through research and development partnerships. Roche maintains its position as a leading innovator and market leader in global CLIA testing through its strong distribution network, integrated laboratory workflow solutions, and dedication to personalized medicine and companion diagnostics.

Danaher Corporation (US)

Danaher Corporation holds a dominant position in the CLIA market through its Beckman Coulter Diagnostics subsidiary, which offers high-throughput immunoassay analyzers and a worldwide assay portfolio used by hospitals and reference laboratories. The Access and DxI immunoassay platforms provide accurate automated testing for oncology and infectious diseases, cardiac markers, endocrine disorders, and metabolic conditions, which enables hospitals to manage their patient load during peak hours. The diagnostics division of Danaher generates substantial financial returns, which helps the company build its market share, while Beckman Coulter uses its extensive testing options, efficient delivery system, and complete laboratory automation products to improve testing efficiency and speed of results. Danaher stands as a top contributor because of its advanced R&D resources, international presence, and partnerships for biomarker research.

Abbott Laboratories (US)

Abbott Laboratories holds the position of market leadership in chemiluminescence immunoassay (CLIA) through its powerful immunodiagnostics systems, extensive testing capabilities, and extensive laboratory network, which operates worldwide. Abbott provides highly automated testing systems through its ARCHITECT and Alinity i immunoassay systems, which hospitals, diagnostic laboratories, and blood screening centers use to diagnose infectious diseases, cardiac markers, oncology, endocrine disorders, and fertility testing. The systems enable laboratories to achieve fast test results by handling high testing volumes; for instance, the ARCHITECT i2000SR can conduct 200 tests per hour, enabling laboratories to operate at high capacity. Abbott's chemiluminescent microparticle immunoassay (CMIA) technology enables early disease detection and screening programs through its ability to deliver high-sensitivity and specificity results, which make it the most accurate testing platform available. The company enhances its market position by expanding its assay menu, building automated laboratory systems, and developing worldwide distribution networks, which facilitate dependable diagnostic services in developed markets and emerging healthcare markets.

Market Ranking

The CLIA market shows moderate to high market concentration because a few global diagnostic companies control most of the market revenue through their broad product lines, advanced testing equipment, proficiency in meeting regulatory requirements, and established connections with hospital and reference laboratory systems. Roche Diagnostics is a leading force in the market through its cobas e immunoassay analyzers and its Elecsys assay portfolio. Danaher’s Beckman Coulter Diagnostics division offers Access and DxI immunoassay systems, which provide customers with flexible testing solutions that automatically process clinical chemistry and immunodiagnostic tests. Abbott Laboratories uses its ARCHITECT and Alinity i platforms to conduct high-sensitivity infectious disease tests, cardiac assessments, hormone evaluations, and blood safety inspections.

Related Reports:

Chemiluminescence Immunoassay Market by Product (Instruments, Consumables), Technology (CLEIA, ECLI, Microparticle CLIA), Sample Type (Blood, Saliva), Application (Oncology, Cardiology), End User (Hospital, Clinical Laboratory) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com